Analysis of Research Publications on Leprosy Drugs Related Adverse Drug Reactions – A Scinetometric Study

IF 0.3 Q4 PHARMACOLOGY & PHARMACY

Current Drug Therapy Pub Date : 2023-07-31 DOI:10.2174/1574885518666230731090607

P. Thangaraju, Himanshu Nirmal Chandu, Hemasri Velmurugan, S. Venkatesan

{"title":"Analysis of Research Publications on Leprosy Drugs Related Adverse Drug Reactions – A Scinetometric Study","authors":"P. Thangaraju, Himanshu Nirmal Chandu, Hemasri Velmurugan, S. Venkatesan","doi":"10.2174/1574885518666230731090607","DOIUrl":null,"url":null,"abstract":"\n\nLeprosy is curable and can be treated with multidrug therapy in the early stages. As a result,\nwe chose a Scientometrics evaluation of leprosy research guides on adverse drug reactions to better\ngrasp the current popularity of drug-related responses. During the 2010-2021 a study with a total of 48\npublications was selected. This study aims to analyze scientometric tools such as frequency distribution, percentage analysis, double-related growth rate, and interaction rate. During the study period, 7\n(14.58%) study publications were submitted in 2018. The related growth rate is identified by decreasing trend and the double time is growing from 2010 to 2021. The 11 published study sizes (22.92%)\nwere provided by top writers, the average Degree of Collaboration is 0.96, and 19 (39.58%) published\nresearch articles by headers. India is the largest supplier of 21 leprosy research publications (43.75%).\nAs India is the most productive country in leprosy research, hence there are four out of the top five institutions that are from the Indian center that is listed among the most productive institutions.\n","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574885518666230731090607","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Leprosy is curable and can be treated with multidrug therapy in the early stages. As a result, we chose a Scientometrics evaluation of leprosy research guides on adverse drug reactions to better grasp the current popularity of drug-related responses. During the 2010-2021 a study with a total of 48 publications was selected. This study aims to analyze scientometric tools such as frequency distribution, percentage analysis, double-related growth rate, and interaction rate. During the study period, 7 (14.58%) study publications were submitted in 2018. The related growth rate is identified by decreasing trend and the double time is growing from 2010 to 2021. The 11 published study sizes (22.92%) were provided by top writers, the average Degree of Collaboration is 0.96, and 19 (39.58%) published research articles by headers. India is the largest supplier of 21 leprosy research publications (43.75%). As India is the most productive country in leprosy research, hence there are four out of the top five institutions that are from the Indian center that is listed among the most productive institutions.

查看原文本刊更多论文

麻风病药物相关不良反应研究报告分析——一项科学计量研究

麻风病是可以治愈的，可以在早期进行多药治疗。因此，我们选择了一份科学计量学评估麻风病药物不良反应研究指南，以更好地了解当前药物相关反应的流行情况。2010-2021年期间，选择了一项共有48份出版物的研究。本研究旨在分析科学计量工具，如频率分布、百分比分析、双相关增长率和交互作用率。在研究期间，2018年提交了7份（14.58%）研究出版物。相关增长率呈下降趋势，从2010年到2021年，两倍时间在增长。11篇已发表的研究规模（22.92%）由顶尖作家提供，平均合作度为0.96，19篇（39.58%）已发表的按标题搜索文章。印度是21种麻风病研究出版物的最大供应国（43.75%）。由于印度是麻风病科研成果最丰富的国家，因此前五名中有四家机构来自印度中心，被列为最具成果的机构之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Drug Therapy PHARMACOLOGY & PHARMACY-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.